Selected research
Industry Research
Drugs Based on Gene Therapy Industry Research Report 2026
Market perspective
The global Drugs Based on Gene Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drugs Based on Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drugs Based on Gene Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drugs Based on Gene Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drugs Based on Gene Therapy include Akcea Therapeutics, Alnylam Pharmaceuticals, AnGes, Biogen, Bluebird bio, Gilead Sciences, Human Stem Cells Institute, Orchard Therapeutics and Sarepta Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drugs Based on Gene Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs Based on Gene Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs Based on Gene Therapy Market by Company
Akcea Therapeutics
Alnylam Pharmaceuticals
AnGes
Biogen
Bluebird bio
Gilead Sciences
Human Stem Cells Institute
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Sunway Biotech
Amgen
Novartis
Drugs Based on Gene Therapy Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Drugs Based on Gene Therapy Segment by Application
Neurological Diseases
Cancer
Other
Drugs Based on Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs Based on Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-viral Gene Therapy
Applications
- Neurological Diseases
- Cancer
- Other
Companies covered
- Akcea Therapeutics
- Alnylam Pharmaceuticals
- AnGes
- Biogen
- Bluebird bio
- Gilead Sciences
- Human Stem Cells Institute
- Orchard Therapeutics
- Sarepta Therapeutics
- SIBIONO
- Spark Therapeutics
- Sunway Biotech
- Amgen
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs Based on Gene Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Viral Gene Therapy
- 2.2.3 Non-viral Gene Therapy
- 2.3 Drugs Based on Gene Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Neurological Diseases
- 2.3.3 Cancer
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Drugs Based on Gene Therapy Breakdown Data by Type
- 3.1 Global Drugs Based on Gene Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs Based on Gene Therapy Forecasted Market Size by Type (2027-2032)
4 Drugs Based on Gene Therapy Breakdown Data by Application
- 4.1 Global Drugs Based on Gene Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs Based on Gene Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs Based on Gene Therapy Market Perspective (2021-2032)
- 5.2 Global Drugs Based on Gene Therapy Growth Trends by Region
- 5.2.1 Global Drugs Based on Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs Based on Gene Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs Based on Gene Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs Based on Gene Therapy Market Dynamics
- 5.3.1 Drugs Based on Gene Therapy Industry Trends
- 5.3.2 Drugs Based on Gene Therapy Market Drivers
- 5.3.3 Drugs Based on Gene Therapy Market Challenges
- 5.3.4 Drugs Based on Gene Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs Based on Gene Therapy Players by Revenue
- 6.1.1 Global Top Drugs Based on Gene Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Drugs Based on Gene Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs Based on Gene Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs Based on Gene Therapy Head Office and Area Served
- 6.4 Global Drugs Based on Gene Therapy Players, Product Type & Application
- 6.5 Global Drugs Based on Gene Therapy Manufacturers Established Date
- 6.6 Global Drugs Based on Gene Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs Based on Gene Therapy Market Size (2021-2032)
- 7.2 North America Drugs Based on Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs Based on Gene Therapy Market Size by Country (2021-2026)
- 7.4 North America Drugs Based on Gene Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs Based on Gene Therapy Market Size (2021-2032)
- 8.2 Europe Drugs Based on Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs Based on Gene Therapy Market Size by Country (2021-2026)
- 8.4 Europe Drugs Based on Gene Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs Based on Gene Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs Based on Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs Based on Gene Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs Based on Gene Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs Based on Gene Therapy Market Size (2021-2032)
- 10.2 South America Drugs Based on Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs Based on Gene Therapy Market Size by Country (2021-2026)
- 10.4 South America Drugs Based on Gene Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs Based on Gene Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs Based on Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs Based on Gene Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs Based on Gene Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Akcea Therapeutics
- 12.1.1 Akcea Therapeutics Company Information
- 12.1.2 Akcea Therapeutics Business Overview
- 12.1.3 Akcea Therapeutics Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.1.4 Akcea Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 12.1.5 Akcea Therapeutics Recent Developments
- 12.2 Alnylam Pharmaceuticals
- 12.2.1 Alnylam Pharmaceuticals Company Information
- 12.2.2 Alnylam Pharmaceuticals Business Overview
- 12.2.3 Alnylam Pharmaceuticals Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.2.4 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Product Portfolio
- 12.2.5 Alnylam Pharmaceuticals Recent Developments
- 12.3 AnGes
- 12.3.1 AnGes Company Information
- 12.3.2 AnGes Business Overview
- 12.3.3 AnGes Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.3.4 AnGes Drugs Based on Gene Therapy Product Portfolio
- 12.3.5 AnGes Recent Developments
- 12.4 Biogen
- 12.4.1 Biogen Company Information
- 12.4.2 Biogen Business Overview
- 12.4.3 Biogen Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.4.4 Biogen Drugs Based on Gene Therapy Product Portfolio
- 12.4.5 Biogen Recent Developments
- 12.5 Bluebird bio
- 12.5.1 Bluebird bio Company Information
- 12.5.2 Bluebird bio Business Overview
- 12.5.3 Bluebird bio Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.5.4 Bluebird bio Drugs Based on Gene Therapy Product Portfolio
- 12.5.5 Bluebird bio Recent Developments
- 12.6 Gilead Sciences
- 12.6.1 Gilead Sciences Company Information
- 12.6.2 Gilead Sciences Business Overview
- 12.6.3 Gilead Sciences Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.6.4 Gilead Sciences Drugs Based on Gene Therapy Product Portfolio
- 12.6.5 Gilead Sciences Recent Developments
- 12.7 Human Stem Cells Institute
- 12.7.1 Human Stem Cells Institute Company Information
- 12.7.2 Human Stem Cells Institute Business Overview
- 12.7.3 Human Stem Cells Institute Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.7.4 Human Stem Cells Institute Drugs Based on Gene Therapy Product Portfolio
- 12.7.5 Human Stem Cells Institute Recent Developments
- 12.8 Orchard Therapeutics
- 12.8.1 Orchard Therapeutics Company Information
- 12.8.2 Orchard Therapeutics Business Overview
- 12.8.3 Orchard Therapeutics Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.8.4 Orchard Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 12.8.5 Orchard Therapeutics Recent Developments
- 12.9 Sarepta Therapeutics
- 12.9.1 Sarepta Therapeutics Company Information
- 12.9.2 Sarepta Therapeutics Business Overview
- 12.9.3 Sarepta Therapeutics Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.9.4 Sarepta Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 12.9.5 Sarepta Therapeutics Recent Developments
- 12.10 SIBIONO
- 12.10.1 SIBIONO Company Information
- 12.10.2 SIBIONO Business Overview
- 12.10.3 SIBIONO Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.10.4 SIBIONO Drugs Based on Gene Therapy Product Portfolio
- 12.10.5 SIBIONO Recent Developments
- 12.11 Spark Therapeutics
- 12.11.1 Spark Therapeutics Company Information
- 12.11.2 Spark Therapeutics Business Overview
- 12.11.3 Spark Therapeutics Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.11.4 Spark Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 12.11.5 Spark Therapeutics Recent Developments
- 12.12 Sunway Biotech
- 12.12.1 Sunway Biotech Company Information
- 12.12.2 Sunway Biotech Business Overview
- 12.12.3 Sunway Biotech Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.12.4 Sunway Biotech Drugs Based on Gene Therapy Product Portfolio
- 12.12.5 Sunway Biotech Recent Developments
- 12.13 Amgen
- 12.13.1 Amgen Company Information
- 12.13.2 Amgen Business Overview
- 12.13.3 Amgen Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.13.4 Amgen Drugs Based on Gene Therapy Product Portfolio
- 12.13.5 Amgen Recent Developments
- 12.14 Novartis
- 12.14.1 Novartis Company Information
- 12.14.2 Novartis Business Overview
- 12.14.3 Novartis Revenue in Drugs Based on Gene Therapy Business (2021-2026)
- 12.14.4 Novartis Drugs Based on Gene Therapy Product Portfolio
- 12.14.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst